2016~2018年南京地区肠促胰素类药物利用情况分析

Analysis of Application of Incretin-based Drugs in Hospitals of Nanjing During 2016-2018

目的:了解2016~2018年南京地区37家医院肠促胰类药物的临床应用情况,评估其变化趋势。方法:对南京地区37家医院2016~2018年肠促胰素类药物的品种、销售金额、构成比、用药频度(DDDs)、限定日费用(DDC)等指标进行统计分析。结果:2016~2018年南京地区37家医院肠促胰素类药物的销售总金额逐年增长,平均年增长率45.14%。沙格列汀、西格列汀3年来销售金额、DDDs值均为排序前2位,且所占总销售金额、总DDDs值比例超过60%。利拉鲁肽和利格列汀增长最为显著。结论:南京地区肠促胰素类药物床应用广泛,使用量和金额均呈快速增长趋势,大部分药物的DDC呈降低趋势。

Objective: To evaluate the application and tendency of hypothalamic incretin-based drugs in 37 hospitals in Nanjing during 2016 to 2018. Methods: Statistics and analysis of incretin-based drugs, sales amount, composition ratio, frequency of drug use(DDDs) and daily drug cost were carried out in 37 hospitals in Nanjing from 2016 to 2018. Results:The total sales of incretin-based drugs increased year by year, with an average annual growth rate of 45.14%. The two drugs of saxagliptin and sitagliptin were ranked in the top 2 of the sales amount and DDDs, and the total sales amount and total DDDs ratio exceeded 60%. Liraglutide and linagliptin increase most significantly. Conclusion:The DPP-4 and GLP-1 hypoglycemic drug beds in Nanjing are widely used, and the usage and amount are showing a rapid growth trend,and the vast majority of daily drug cost is decreasing.